CROSS SYNC is an AI clinical decision support startup that improves clinical safety by detecting sudden patient changes earlier through AI analysis of physical findings obtained from live video feeds.
We have paid installation of iBSEN at 1 hospital in Japan, as well as have received inquiries from 22 other hospitals so far. In addition, we are in discussions about POC trials with stake holders at one hospital in India and one hospital in Taiwan.
Regarding finance, we have procured about $2.5M in research funding from the Japan Agency for Medical Research and Development, to promote the development of AI technology and to commercialize the technology as a SAMD in Japan.
Problem or Opportunity
Due to today’s COVID-19 pandemic, a lot of acute care hospitals suffer from the shortage of intensive care specialist physicians, which makes more than 85% of ICUs operate without intensivist care in the US. In such tragic circumstances, it is not possible for other ICU staffs to properly and timely assess the severity of the patient’s illness, resulting in many medical errors and a decline in the quality of intensive care. In fact, in ICUs without intensivist care, there are increasing risks of ICU mortality by 15%, mortality from septic shock by 17%, mortality from ARDS by 10%.
Solution (product or service)
Our AI platform iBSEN can monitor patients in the ICU continuously in real-time. It combines standard telemetry data in hospitals with data ingested from a live video feed, which allows clinical staffs to evaluate patients conditions more accurately from anywhere from your smartphones. By enhancing the quality of information sharing, iBSEN can assist any physicians and nurses in accurately assessing the severity of patients conditions, which can facilitate rapid patient response and contribute to improved patient outcomes.
The business model of CROSS SYNC is a B2B business targeting hospitals and healthcare providers, especially acute care hospitals.
Our product, iBSEN, will be sold as a software license. The unit price per hospital is USD100K per 20 ICU beds. The sales models are firstly through direct sales by ourselves and secondly through distributors such Nihon Kohden, Konica Minolta and Toyota Tsusho.
Incubation/Acceleration programs accomplishment
1. The Springboard Program in Yokohama with San Diego CONNECT Venture Group (2020/09-2020/11)
2. Techstars Founder Catalyst Japan (2021/02-2021/04)
3. Microsoft for Startups (2021/08-2022/08)
4. NVIDIA Inception Program (2021/09-)
5. Qualcomm Innovate in Taiwan Challenge 2021 (2021/09-2021/11, *Invited as extension program of #2)
6. Boston x Yokohama Life Science Bootcamp with Cambridge Innovation Center (2022/02-2022/04)
7. BE Acceleration Program with Taipei Medical University (2022/02-2022/08)